Endocrinology

INTRODUCTION

Diabetic retinopathy is the primary cause of blindness in 20-64 years old. Recent studies support that patients with diabetes after 10-15 years will develop diabetic retinopathy or have some degree of retinal damage.  The treatment options mainly focus on the last stages of the disease. Although it is a challenge for health, the science is lagging in treatment options, especially, for the early stages of the disease where the excessive blood glucose damages the vessels walls and leads to gradually degeneration of the vessels increasing the oxidative stress and activating the inflammation.

In addition to diabetic retinopathy, patients with diabetes have an increased risk of developing vein occlusion. Although, in this particular case atherosclerosis is the most common cause. In vein occlusion, the retinal vein is blocked, preventing normal blood flow and leading to inflammation.

PRODUCT INFORMATION

Retinoaspis is a specialized nutraceutical for the prevention and treatment of diabetic retinopathy and retinal vein occlusion.

Retinoaspis manages diabetic retinopathy by supporting the metabolism, structure and function of retinal cells. Retinoaspis has a strong anti-inflammatory effect by promoting the production of anti-inflammatory cytokines. A key anti-inflammatory component is docosahexaenoic acid (DHA), which is a necessary component for the normal function of the organism and cannot be synthesized by itself. Retinoaspis also has an antioxidant effect, providing the necessary antioxidant mechanism in the retina. Astaxanthin, which is contained in the product, is literally hundreds of times stronger than other antioxidant molecules. Astaxanthin comes from the algae of the genus Haematococcus pluvialis and is a natural carotenoid. Retinoaspis covers the body's vitamin needs, regulates homocysteine levels and provides an additional anti-inflammatory effect with vitamin B12.

INTRODUCTION

Graves’ disease, also known as thyroid eye disease, is an autoimmune disease in which, for unknown reason, the immune system attacks to healthy tissue in thyroid gland. Its name comes from the Irish doctor Robert Graves who was the first to identify the disease. In Graves’ disease the thyroid gland produces an excess of thyroid hormone. Graves’ disease is the most common cause of hyperthyroidism and it mainly affects people aged 30–50, but it can also affect children and older people. Graves’ disease can affect the heart, bones, liver and skin. Existing treatment options focus on regulation of thyroid hormone levels. This disease can also cause eye disease symptoms, such as bulging, irritated eyes, swelling tissues around the eyes, light sensitivity, pressure and pain, double and blurred vision.

PRODUCT INFORMATION

Eyeaspis DE caps is a specially designed product that manages dry eye disease and helps to decongest clogged glands. Eyeaspis DE caps has a proven anti-inflammatory effect and provides fatty acids as the main ingredient of meibomian gland to produce the right quality and quantity of the lipid layer (meibum).

Key components of the lipid layer with a strong anti-inflammatory effect are ω-3 fatty acids such as eicosapentaenoic acid (EPA) which is essential fatty acid for general function of the organism and which the body cannot synthesize by itself.

Eyeaspis DE caps has a strong anti-inflammatory effect with the re-esterified triglyceride EPA as the main ingredient and antioxidant effect due to maqui berry extract (35% delphinidins). In addition, Eyeaspis DE caps covers the basic needs of the body in vitamin D3 with 1000 IU and vitamin B12.

Coming Soon!